Skip Navigation


Hum. Reprod. Advance Access first published online on September 5, 2006
This version published online on October 17, 2006
Human Reproduction, doi:10.1093/humrep/del335
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
22/1/97    most recent
del335v2
del335v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Demirol, A.
Right arrow Articles by Gurgan, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demirol, A.
Right arrow Articles by Gurgan, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received January 30, 2006
Revised May 13, 2006
Accepted July 24, 2006

Article

Comparison of different gonadotrophin preparations in intrauterine insemination cycles for the treatment of unexplained infertility: a prospective, randomized study

A. Demirol 1 * and T. Gurgan 2

1 Clinic Women Health, Infertility and IVF Center, Hacettepe University, Ankara, Turkey
2 Clinic Women Health, Infertility and IVF Center, Hacettepe University, Ankara, Turkey; Department of Obstetrics and Gynecology, Reproductive Endocrinology and IVF Unit, Hacettepe University, Ankara, Turkey

* To whom correspondence should be addressed.
A. Demirol, E-mail: ademirol{at}gmail.com


  Abstract

BACKGROUND: A comparison of the effectiveness of different gonadotrophin preparations in intrauterine insemination (IUI) cycles for patients with unexplained infertility was performed. METHODS: Two hundred and forty-one patients were prospectively randomized using computer-generated random numbers into three groups: 81 in the Follitropin {alpha} (Group I), 80 in the urinary FSH (uFSH) (Group II) and 80 in the hMG (Group III). The primary outcome was clinical pregnancy rate with duration of stimulation, total gonadotrophin dose, number of dominant follicles, clinical pregnancy rate, multiple pregnancy, miscarriage rate and ovarian hyperstimulation syndrome (OHSS) rate being secondary outcomes. RESULTS: Clinical pregnancy rate was significantly higher in the rFSH group (25.9% in Follitropin {alpha}, 13.8% in uFSH and 12.5% in HMG groups; P = 0.04). There was no significant difference in terms of duration of stimulation, but mean FSH dose consumed per cycle was significantly lower in the recombinant FSH (rFSH) group compared with others (825 IU in Follitropin {alpha}, 1107 IU in uFSH and 1197 IU in HMG groups; P = 0.001). The number of follicles ≥16 mm diameter was significantly higher in the rFSH group compared with the uFSH and HMG groups (2.6 in Follitropin {alpha}, 1.3 in uFSH and 1.4 in HMG groups; P = 0.001). CONCLUSION: rFSH may result in a better outcome in IUI cycles for unexplained infertility.

Keywords: gonadotrophin/IUI/ovarian stimulation/recombinant FSH/unexplained infertility.

This is a new version of this article as a previously omitted reference has now been added to the reference list.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.